Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

443 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1.
Bhatt RS, Berjis A, Konge JC, Mahoney KM, Klee AN, Freeman SS, Chen CH, Jegede OA, Catalano PJ, Pignon JC, Sticco-Ivins M, Zhu B, Hua P, Soden J, Zhu J, McDermott DF, Arulanandam AR, Signoretti S, Freeman GJ. Bhatt RS, et al. Among authors: freeman ss, freeman gj. Cancer Immunol Res. 2021 Feb;9(2):156-169. doi: 10.1158/2326-6066.CIR-20-0315. Epub 2020 Nov 23. Cancer Immunol Res. 2021. PMID: 33229411 Free PMC article.
PD-L2 is a second ligand for PD-1 and inhibits T cell activation.
Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, Greenfield EA, Bourque K, Boussiotis VA, Carter LL, Carreno BM, Malenkovich N, Nishimura H, Okazaki T, Honjo T, Sharpe AH, Freeman GJ. Latchman Y, et al. Among authors: freeman gj. Nat Immunol. 2001 Mar;2(3):261-8. doi: 10.1038/85330. Nat Immunol. 2001. PMID: 11224527
PD-1 and its ligands in tolerance and immunity.
Keir ME, Butte MJ, Freeman GJ, Sharpe AH. Keir ME, et al. Among authors: freeman gj. Annu Rev Immunol. 2008;26:677-704. doi: 10.1146/annurev.immunol.26.021607.090331. Annu Rev Immunol. 2008. PMID: 18173375 Free PMC article. Review.
Interaction of human PD-L1 and B7-1.
Butte MJ, Peña-Cruz V, Kim MJ, Freeman GJ, Sharpe AH. Butte MJ, et al. Among authors: freeman gj. Mol Immunol. 2008 Aug;45(13):3567-72. doi: 10.1016/j.molimm.2008.05.014. Epub 2008 Jun 27. Mol Immunol. 2008. PMID: 18585785 Free PMC article.
The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo.
Yang J, Riella LV, Chock S, Liu T, Zhao X, Yuan X, Paterson AM, Watanabe T, Vanguri V, Yagita H, Azuma M, Blazar BR, Freeman GJ, Rodig SJ, Sharpe AH, Chandraker A, Sayegh MH. Yang J, et al. Among authors: freeman gj. J Immunol. 2011 Aug 1;187(3):1113-9. doi: 10.4049/jimmunol.1100056. Epub 2011 Jun 22. J Immunol. 2011. PMID: 21697455 Free PMC article.
443 results